MediWound misses Q4 revenue on U.S. government shutdown, reaffirms FY revenue guidance

Mediwound

05/03/2026 12:21

Overview

Israel biotechnology firm's Q4 revenue missed analyst expectations

Adjusted EBITDA loss for Q4 beat analyst expectations

Company's Q4 revenue decline due to U.S. government shutdown affecting budget approvals

Outlook

Company reaffirms revenue guidance of $24–26 mln for 2026

Company expects regulatory approvals for expanded NexoBrid manufacturing in 2026

Result Drivers

REVENUE IMPACT - Q4 revenue decline due to U.S. government shutdown delaying budget approvals and new contracts

Company press release: ID:nGNX71FjLv

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$1.9 mln
$6.11 mln (5 Analysts)
Q4 EPS
-$0.56
Q4 Net Income
-$7.2 mln
Q4 Adjusted EBITDA
Beat
-$6.5 mln
-$7.27 mln (2 Analysts)
Q4 Gross Profit
$300,000
Q4 Operating Income
-$7.8 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Mediwound Ltd is $32.00, about 81.8% above its March 4 closing price of $17.60

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)